This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 19:16, 19 April 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 19:16, 19 April 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation ()(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Other names | LY-503,430; (R)-4'--biphenyl-4-carboxylic acid methylamide |
| Routes of administration | oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C20H25FN2O3S |
| Molar mass | 392.49 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
| (verify) | |
LY-503,430 is an ampakine drug developed by Eli Lilly.
LY-503,430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus and striatum. It is orally active and the main application it is currently being developed for is treatment of Parkinson's Disease although it has also been proposed to be useful in the treatment of Alzheimer's Disease, depression and schizophrenia.
References
- O'neill, MJ; Murray, TK; Clay, MP; Lindstrom, T; Yang, CR; Nisenbaum, ES (2005). "LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease". CNS drug reviews. 11 (1): 77–96. doi:10.1111/j.1527-3458.2005.tb00037.x. PMID 15867954.
- Murray, TK; Whalley, K; Robinson, CS; Ward, MA; Hicks, CA; Lodge, D; Vandergriff, JL; Baumbarger, P; Siuda, E (2003). "LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease". The Journal of pharmacology and experimental therapeutics. 306 (2): 752–62. doi:10.1124/jpet.103.049445. PMID 12730350.
- Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). "Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors". The Journal of pharmacology and experimental therapeutics. 319 (1): 293–8. doi:10.1124/jpet.106.105734. PMID 16803862.
- O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). "AMPA receptor potentiators for the treatment of CNS disorders". Current drug targets. CNS and neurological disorders. 3 (3): 181–94. doi:10.2174/1568007043337508. PMID 15180479.
- O'neill, MJ; Witkin, JM (2007). "AMPA receptor potentiators: application for depression and Parkinson's disease". Current drug targets. 8 (5): 603–20. doi:10.2174/138945007780618517. PMID 17504104.
| Psychostimulants, agents used for ADHD, and nootropics (N06B) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| N06BA Centrally acting sympathomimetics | |||||||||
| N06BC Xanthine derivatives | |||||||||
| N06BX Other psychostimulants and nootropics | |||||||||
| |||||||||
 | This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |